{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT02099058","nct_id":"NCT02099058","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02099058. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.","label":"Monotherapy Telisotuzumab vedotin (21-day dosing cycles)","type":"EXPERIMENTAL"},{"description":"Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.","label":"Monotherapy Telisotuzumab vedotin(28-day dosing cycles)","type":"EXPERIMENTAL"},{"description":"Telisotuzumab vedotin will be administered every 14 days on a 28-day dosing cycle.","label":"Monotherapy Expansion Cohort","type":"EXPERIMENTAL"},{"description":"Telisotuzumab vedotin to be evaluated with Erlotinib.","label":"Arm A (Telisotuzumab vedotin plus Erlotinib)","type":"EXPERIMENTAL"},{"description":"Telisotuzumab vedotin to be evaluated with Nivolumab.","label":"Arm D (Telisotuzumab vedotin plus Nivolumab)","type":"EXPERIMENTAL"},{"description":"Telisotuzumab vedotin to be evaluated with Osimertinib.","label":"Arm E (Telisotuzumab vedotin plus Osimertinib)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-08","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors Cancer"],"enrollment":{"count":237,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Telisotuzumab vedotin","otherNames":["ABBV-399"],"type":"DRUG"},{"name":"Telisotuzumab vedotin","otherNames":["ABBV-399"],"type":"DRUG"},{"name":"Erlotinib","otherNames":[],"type":"DRUG"}],"last_update":"2025-08-14","lead_sponsor":"AbbVie","official_title":"A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants with Adverse Events","timeFrame":"Up to 24 Months"},{"measure":"Recommended Phase 2 Dose (RPTD) of ABBV-399 when Administered as Monotherapy and in Combination with Osimertinib, Erlotinib or Nivolumab","timeFrame":"Up to 24 Months"},{"measure":"Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)","timeFrame":"Up to 24 months"},{"measure":"Maximum observed plasma concentration (Cmax)","timeFrame":"Up to 24 months"},{"measure":"Time to Cmax (Tmax)","timeFrame":"Up to 24 months"},{"measure":"Terminal elimination half life","timeFrame":"Up to 24 months"}],"references":[{"citation":"Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025 May;36(5):583-591. doi: 10.1016/j.annonc.2025.01.001. Epub 2025 Jan 11.","pmid":"39805351","type":"DERIVED"},{"citation":"Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Epub 2022 Oct 26.","pmid":"36288547","type":"DERIVED"},{"citation":"Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 Nov 1;27(21):5781-5792. doi: 10.1158/1078-0432.CCR-21-0765. Epub 2021 Aug 23.","pmid":"34426443","type":"DERIVED"},{"citation":"Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4.","pmid":"30285518","type":"DERIVED"}],"start_date":{"date":"2014-01-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT02099058"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02099058"}